The aim of the 3rd LUNG CANCER Network “From the Bench to the Bedside” is to narrow the distance between the lab bench and the patient’s bed, between the clinical trials outcome and the routine practice, by bringing together basic scientists, clinical researchers and lung cancer specialists.
Main Topics:
- End points of translational research clinical trials
- Prognistic and predictive tumor markers
- The molecular pathology of non-smoker lung cancer pts
- Gender discrepancies in lung cancer
- NSCLS driver oncogenes
- EGFR mutation heterogeneity
- Newer generation TKIs inhibitors
- The Met,, K-ras and mTOR/PI3k pathways
Contacts:
Tel: 30 210 98 20 032
Fax: 30 210 98 81 303
E-mail: [email protected]